AbbVie Inc.

Analyst Ratings Synthesis

The supplied consensus is Buy across 22 analysts, with price targets ranging from $265 to $300 and a mean of $281. The target spread is therefore $35, with the least bullish estimate only modestly above the reported $261.77 close and the most bullish materially higher. The supplied evidence does not identify which analysts set the $265 and $300 targets, so the most and least bullish firms cannot be named. No attributable rating or target revision during the week is documented. The substantive disagreement centers on whether immunology growth, including SKYRIZI, pipeline wins and broader neuroscience expansion can sustain earnings, versus the risk that a SKYRIZI slowdown, portfolio concentration and a lower dividend yield limit upside.

• What Is AbbVie (ABBV) Stock and ABBVx Tokenized Stock?
• AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
• AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
• AbbVie’s depression drug improved mood and daily life in real-world studies
• AbbVie (ABBV) Could Be 4% Undervalued After Phase 3 Trial Wins